Treatment is Waiting

In 2014, Ghobrial launched Dana-Farber’s new Center for Prevention of Progression of Blood Cancers, which sees patients with early myelodysplastic syndromes (MDS), early CLL, monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma, which can progress to multiple myeloma, in order to learn more about the natural history of these cancers and develop therapies that could potentially prevent progression. +read more

Dana-Farber Cancer Institute logo
Center for Prevention of Progression of Blood Cancers

© 2018 Dana-Farber Cancer Institute |  Terms of Use  |   Privacy Policy